Document detail
ID

oai:pubmedcentral.nih.gov:7823...

Topic
Research Article
Author
Brázda, Václav Porubiaková, Otília Cantara, Alessio Bohálová, Natália Coufal, Jan Bartas, Martin Fojta, Miroslav Mergny, Jean-Louis
Langue
en
Editor

BioMed Central

Category

BMC Genomics

Year

2021

listing date

12/4/2023

Keywords
influenza genome pqs g4-ea-h1n1 genomes
Metrics

Abstract

BACKGROUND: Influenza viruses are dangerous pathogens.

Seventy-Seven genomes of recently emerged genotype 4 reassortant Eurasian avian-like H1N1 virus (G4-EA-H1N1) are currently available.

We investigated the presence and variation of potential G-quadruplex forming sequences (PQS), which can serve as targets for antiviral treatment.

RESULTS: PQS were identified in all 77 genomes.

The total number of PQS in G4-EA-H1N1 genomes was 571.

Interestingly, the number of PQS per genome in individual close relative viruses varied from 4 to 12.

PQS were not randomly distributed in the 8 segments of the G4-EA-H1N1 genome, the highest frequency of PQS being found in the NP segment (1.39 per 1000 nt), which is considered a potential target for antiviral therapy.

In contrast, no PQS was found in the NS segment.

Analyses of variability pointed the importance of some PQS; even if genome variation of influenza virus is extreme, the PQS with the highest G4Hunter score is the most conserved in all tested genomes.

G-quadruplex formation in vitro was experimentally confirmed using spectroscopic methods.

CONCLUSIONS: The results presented here hint several G-quadruplex-forming sequences in G4-EA-H1N1 genomes, that could provide good therapeutic targets.

Brázda, Václav,Porubiaková, Otília,Cantara, Alessio,Bohálová, Natália,Coufal, Jan,Bartas, Martin,Fojta, Miroslav,Mergny, Jean-Louis, 2021, G-quadruplexes in H1N1 influenza genomes, BioMed Central

Document

Open Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw